| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Institut National de la Santé et de la Recherche Médicale U517, Dijon, France; 2 Institut National de la Santé et de la Recherche Médicale U563, Institut Claudius Régaud, Toulouse, France; 3 Institut National de la Santé et de la Recherche Médicale U620, Rennes, France; 4 Institut National de la Santé et de la Recherche Médicale U498, Dijon, France; and 5 Laboratoire de Biologie Cellulaire et Végétale, Rennes, France
We have shown previously that the death receptor CD95 could contribute to anticancer drug-induced apoptosis of colon cancer cells. In addition, anticancer drugs cooperate with CD95 cognate ligand or agonistic antibodies to trigger cancer cell apoptosis. In the present study, we show that the anticancer drug cisplatin induces clustering of CD95 at the surface of the human colon cancer cell line HT29, an event inhibited by the inhibitor of acid sphingomyelinase (aSMase) imipramine. The cholesterol sequestering agent nystatin also prevents cisplatin-induced CD95 clustering and decreases HT29 cell sensitivity to cisplatin-induced apoptosis and the synergy between cisplatin and anti-CD95 agonistic antibodies. CD95, together with the adaptor molecule Fas-associated death domain and procaspase-8, is redistributed into cholesterol- and sphingolipid-enriched cell fractions after cisplatin treatment, suggesting plasma membrane raft involvement. Interestingly, nystatin prevents the translocation of the aSMase to the extracellular surface of plasma membrane and the production of ceramide, suggesting that these early events require raft integrity. In addition, nystatin prevents cisplatin-induced transient increase in plasma membrane fluidity that could be required for CD95 translocation. Together, these results demonstrate that cisplatin activates aSMase and induces ceramide production, which triggers the redistribution of CD95 into the plasma membrane rafts. Such redistribution contributes to cell death and sensitizes tumor cells to CD95-mediated apoptosis.
This article has been cited by other articles:
![]() |
S. Uhlig and E. Gulbins Sphingolipids in the Lungs Am. J. Respir. Crit. Care Med., December 1, 2008; 178(11): 1100 - 1114. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Bose, L. Maurmann, R. J. Mishur, L. Yasui, S. Gupta, W. S. Grayburn, H. Hofstetter, and T. Salley Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells PNAS, November 25, 2008; 105(47): 18314 - 18319. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Smith and E. H. Schuchman The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases FASEB J, October 1, 2008; 22(10): 3419 - 3431. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-J. Jia, S. Jin, F. Zhang, F. Yi, W. L. Dewey, and P.-L. Li Formation and function of ceramide-enriched membrane platforms with CD38 during M1-receptor stimulation in bovine coronary arterial myocytes Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1743 - H1752. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. H. Zeidan, R. W. Jenkins, and Y. A. Hannun Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway J. Cell Biol., April 21, 2008; 181(2): 335 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Beneteau, M. Pizon, B. Chaigne-Delalande, S. Daburon, P. Moreau, F. De Giorgi, F. Ichas, A. Rebillard, M.-T. Dimanche-Boitrel, J.-L. Taupin, et al. Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway Mol. Cancer Res., April 1, 2008; 6(4): 604 - 613. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yoon, A. Terada, and H. Kita CD66b Regulates Adhesion and Activation of Human Eosinophils J. Immunol., December 15, 2007; 179(12): 8454 - 8462. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Sharma, C. Joseph, S. Ghosh, A. Agarwal, M. K. Mishra, and E. Sen Kaempferol induces apoptosis in glioblastoma cells through oxidative stress Mol. Cancer Ther., September 1, 2007; 6(9): 2544 - 2553. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Mitchell, P. Kabolizadeh, J. Ryan, J. D. Roberts, A. Yacoub, D. T. Curiel, P. B. Fisher, M. P. Hagan, N. P. Farrell, S. Grant, et al. Low-Dose BBR3610 Toxicity in Colon Cancer Cells Is p53-Independent and Enhanced by Inhibition of Epidermal Growth Factor Receptor (ERBB1)-Phosphatidyl Inositol 3 Kinase Signaling Mol. Pharmacol., September 1, 2007; 72(3): 704 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Perrotta, L. Bizzozero, S. Falcone, P. Rovere-Querini, A. Prinetti, E. H. Schuchman, S. Sonnino, A. A. Manfredi, and E. Clementi Nitric Oxide Boosts Chemoimmunotherapy via Inhibition of Acid Sphingomyelinase in a Mouse Model of Melanoma Cancer Res., August 15, 2007; 67(16): 7559 - 7564. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rebillard, X. Tekpli, O. Meurette, O. Sergent, G. LeMoigne-Muller, L. Vernhet, M. Gorria, M. Chevanne, M. Christmann, B. Kaina, et al. Cisplatin-Induced Apoptosis Involves Membrane Fluidification via Inhibition of NHE1 in Human Colon Cancer Cells Cancer Res., August 15, 2007; 67(16): 7865 - 7874. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gajate and F. Mollinedo Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts Blood, January 15, 2007; 109(2): 711 - 719. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Huang, H.-M. Shen, G. Shui, M. R. Wenk, and C.-N. Ong Emodin Inhibits Tumor Cell Adhesion through Disruption of the Membrane Lipid Raft-Associated Integrin Signaling Pathway Cancer Res., June 1, 2006; 66(11): 5807 - 5815. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-L. Hsiao, W.-S. Wang, P.-M. Chen, and Y. Su Overexpression of thymosin {beta}-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively Carcinogenesis, May 1, 2006; 27(5): 936 - 944. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Gulbins and P. L. Li Physiological and pathophysiological aspects of ceramide Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R11 - R26. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Martin, D. C. Phillips, K. Szekely-Szucs, L. Elghazi, F. Desmots, and J. A. Houghton Cyclooxygenase-2 Inhibition Sensitizes Human Colon Carcinoma Cells to TRAIL-Induced Apoptosis through Clustering of DR5 and Concentrating Death-Inducing Signaling Complex Components into Ceramide-Enriched Caveolae Cancer Res., December 15, 2005; 65(24): 11447 - 11458. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Voelkel-Johnson, Y. A. Hannun, and A. El-Zawahry Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein Mol. Cancer Ther., September 1, 2005; 4(9): 1320 - 1327. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Rotolo, J. Zhang, M. Donepudi, H. Lee, Z. Fuks, and R. Kolesnick Caspase-dependent and -independent Activation of Acid Sphingomyelinase Signaling J. Biol. Chem., July 15, 2005; 280(28): 26425 - 26434. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gajate and F. Mollinedo Cytoskeleton-mediated Death Receptor and Ligand Concentration in Lipid Rafts Forms Apoptosis-promoting Clusters in Cancer Chemotherapy J. Biol. Chem., March 25, 2005; 280(12): 11641 - 11647. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |